Literature DB >> 11764091

Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis.

C Atzori1, B Ghetti, R Piva, A N Srinivasan, P Zolo, M B Delisle, S S Mirra, A Migheli.   

Abstract

JNK and p38, two members of the MAP kinase family, are strongly induced by various stresses including oxidative stress and have been involved in regulation of apoptosis. As both kinases phosphorylate tau protein in vitro, we have investigated their immunohistochemical localization in a group of neurodegenerative diseases characterized by intracellular deposits of hyperphosphorylated tau. Cases included Alzheimer disease, Pick disease, progressive supranuclear palsy, corticobasal degeneration, Gerstmann-Sträussler-Scheinker disease-Indiana kindred, and frontotemporal dementia with parkinsonism linked to chromosome 17. In all tissue samples, strong immunoreactivity for both MAP kinases was found in the same neuronal or glial cells that contained tau-positive deposits. By double immunohistochemistry, JNK and p38 colocalized with tau in the inclusions. Analysis of apoptosis-related changes (DNA fragmentation, activated caspase-3) showed that the expression of JNK and p38 was unrelated to activation of an apoptotic cascade. Our data indicate that phospho-JNK and phospho-p38 are associated with hyperphosphorylated tau in a variety of abnormal tau inclusions, suggesting that these kinases may play a role in the development of degenerative diseases with tau pathology.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11764091     DOI: 10.1093/jnen/60.12.1190

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  46 in total

Review 1.  Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.

Authors:  Lian-Feng Lin; Huan-Min Luo
Journal:  Neurosci Bull       Date:  2011-02       Impact factor: 5.203

Review 2.  Oxidative stress, cell cycle, and neurodegeneration.

Authors:  Jeffrey A Klein; Susan L Ackerman
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

3.  Neurodegenerative tauopathy in the worm.

Authors:  Michel Goedert
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-11       Impact factor: 11.205

4.  Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice.

Authors:  Masashi Kitazawa; Kim N Green; Antonella Caccamo; Frank M LaFerla
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

Review 5.  Targeting protein kinases in central nervous system disorders.

Authors:  Laura K Chico; Linda J Van Eldik; D Martin Watterson
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

Review 6.  A novel perspective on tau in Alzheimer's disease.

Authors:  D J Bonda; R J Castellani; X Zhu; A Nunomura; H-g Lee; G Perry; M A Smith
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

7.  Mitochondrial Dysfunction Triggers Synaptic Deficits via Activation of p38 MAP Kinase Signaling in Differentiated Alzheimer's Disease Trans-Mitochondrial Cybrid Cells.

Authors:  Qing Yu; Fang Du; Justin T Douglas; Haiyang Yu; Shirley ShiDu Yan; Shi Fang Yan
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

8.  5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease.

Authors:  Jin Chu; Phillip F Giannopoulos; Carolina Ceballos-Diaz; Todd E Golde; Domenico Praticò
Journal:  Ann Neurol       Date:  2012-09       Impact factor: 10.422

Review 9.  Oxidative stress signaling in Alzheimer's disease.

Authors:  B Su; X Wang; A Nunomura; P I Moreira; H-gon Lee; G Perry; M A Smith; X Zhu
Journal:  Curr Alzheimer Res       Date:  2008-12       Impact factor: 3.498

Review 10.  The p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target.

Authors:  Aaron S Borders; Lucia de Almeida; Linda J Van Eldik; D Martin Watterson
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.